<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02967640</url>
  </required_header>
  <id_info>
    <org_study_id>2012/1199</org_study_id>
    <secondary_id>2012-002782-35</secondary_id>
    <nct_id>NCT02967640</nct_id>
  </id_info>
  <brief_title>Does Subacromial Injection With Glutamate Receptor Antagonist, Ketamine, Attenuate Pain in Rotator Cuff Tendinopathy?</brief_title>
  <official_title>Does Subacromial Injection With Glutamate Receptor (NMDAR) Antagonist, Ketamine, Attenuate Pain in Rotator Cuff Tendinopathy?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helse Møre og Romsdal HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helse Møre og Romsdal HF</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of the present study is that in patients with rotator cuff tendinopathy a&#xD;
      specific pharmacological blocking of peripheral glutamate-receptor N-methyl-d-aspartate&#xD;
      receptor type1 (NMDAR) glutamate receptors will result in pain alleviation. Activated NMDAR1&#xD;
      has been demonstrated to be crucial for pain regulation in various pain disorders, and in&#xD;
      biopsies from patients with tendinopathy, NMDAR1 was found to be activated.&#xD;
&#xD;
      To test this hypothesis a specific NMDA receptor antagonist, ketalar (ketamine), will be&#xD;
      injected guided by ultrasound into the subacromial space in patients with rotator cuff&#xD;
      tendinopathy, and subsequently the pain response will be assessed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Supraspinatus pressure pain threshold</measure>
    <time_frame>30 minutes</time_frame>
    <description>Comparison of supraspinatus pressure pain threshold measured in Lbs/cm3, after selective N-methyl-d-aspartate receptor type 1 blocking by ketalar injection subacromially controlled against ringer acetate injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Western Ontario Rotator Cuff Index</measure>
    <time_frame>30 minutes</time_frame>
    <description>Comparisons of shoulder function assessed by Western Ontario Rotator Cuff index in the same patient group after selective N-methyl-d-aspartate receptor type 1 blocking by ketalar injection subacromially controlled against Ringer acetate injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxford Shoulder Score</measure>
    <time_frame>30 minutes</time_frame>
    <description>Comparison of shoulder function assessed by Oxford Shoulder Score after selective N-methyl-d-aspartate receptor type 1 blocking by ketalar injection subacromially controlled against Ringer acetate injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>30 minutes</time_frame>
    <description>Comparison of pain assessed by a visual analogue scale both at rest and abduction, after selective N-methyl-d-aspartate receptor type 1 blocking by ketalar injection subacromially controlled against Ringer acetate injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pressure pain tolerance</measure>
    <time_frame>30 minutes</time_frame>
    <description>Comparison of pressure pain tolerance measured in Lbs/cm3, both at rest and abduction, after selective N-methyl-d-aspartate receptor type 1 blocking by ketalar injection subacromially controlled against Ringer acetate injection.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Rotator Cuff Tendinitis</condition>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Ketalar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ketalar injection, subacromial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>physiological sodium chloride (NaCl 9%) injection, subacromial</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketalar</intervention_name>
    <description>2,5 ml - if well tolerated immediately followed by another 2,5 ml - of an approximately 1 mg/ml ketalar solution (1 ml of ketalar 10 mg/ml + 9 ml of NaCl 9%) injected 2 times with 1-12 weeks between each injection</description>
    <arm_group_label>Ketalar</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Ketamine</other_name>
    <other_name>Ketanest</other_name>
    <other_name>Ketaset</other_name>
    <other_name>Calipsol</other_name>
    <other_name>Kalipsol</other_name>
    <other_name>Calypsol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl 9%</intervention_name>
    <description>2,5 ml - if well tolerated immediately followed by another 2,5 ml - of a 9% NaCl solution injected 2 times with 1-12 weeks between each injection</description>
    <arm_group_label>Ketalar</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of rotator cuff tendinopathy by exercise-related shoulder pain with positive&#xD;
             impingement tests as described by Hawkins and Neers, and MRI findings consistent with&#xD;
             tendinopathy.&#xD;
&#xD;
          -  Symptom duration at least 1 year to ensure neuronal ingrowth and NMDAR expression&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous surgery in any shoulder.&#xD;
&#xD;
          -  previous cortisone use, either as injections or orally&#xD;
&#xD;
          -  symptoms or signs of cervicobrachialgia or polyneuropathy&#xD;
&#xD;
          -  full thickness rotator cuff ruptures verified by MRI&#xD;
&#xD;
          -  primary inflammatory mediated pain, hence, patients with glenohumeral arthrosis,&#xD;
             glenohumeral arthritis or systemic disorders predisposing for arthritis&#xD;
&#xD;
          -  a central component of pain perception manifested by radiating pain in the involved&#xD;
             limb; implying worse outcome after subacromial decompression.&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  breastfeeding&#xD;
&#xD;
          -  reduced liver function (Increased serum bilirubin, ASAT or ALAT), decompensated heart&#xD;
             failure (NYHA class 3-4)&#xD;
&#xD;
          -  increased intracranial pressure or disease of the central nervous system (CNS)&#xD;
&#xD;
          -  chronic alcoholism&#xD;
&#xD;
          -  epilepsy&#xD;
&#xD;
          -  psychiatric disease, increased intraocular pressure&#xD;
&#xD;
          -  acute intermittent porphyria&#xD;
&#xD;
          -  hyperthyroidism&#xD;
&#xD;
          -  use of thyroid hormones&#xD;
&#xD;
          -  upper respiratory tract infections&#xD;
&#xD;
          -  pneumonia&#xD;
&#xD;
          -  intracranial lesions&#xD;
&#xD;
          -  acute head injuries&#xD;
&#xD;
          -  ocular injuries&#xD;
&#xD;
          -  hydrocephalus&#xD;
&#xD;
          -  risk factors predisposing for intra-articular bleeding&#xD;
&#xD;
          -  increased risk of infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oystein B Lian, md phd</last_name>
    <role>Study Chair</role>
    <affiliation>Helse Nord-Trøndelag HF</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ola M Lian, md</last_name>
    <phone>+47 272847</phone>
    <email>Ola.Midtsether.Lian@helse-mr.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Orthopedic Surgery, Kristiansund Hospital</name>
      <address>
        <city>Kristiansund</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ola M Lian, MD</last_name>
      <email>Ola.Midtsether.Lian@helse-mr.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 16, 2016</study_first_submitted>
  <study_first_submitted_qc>November 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2016</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ketamine</keyword>
  <keyword>Analgesics</keyword>
  <keyword>Excitatory Amino Acid Antagonists</keyword>
  <keyword>Receptors, Glutamate</keyword>
  <keyword>Shoulder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tendinopathy</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Rotator Cuff Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

